Baird Sets $26 Target for Caris Life Sciences After 20% Case Growth
On February 17, Baird launched coverage of Caris Life Sciences with an Outperform rating and a $26 price target, citing comprehensive molecular profiling and machine learning algorithms. Q4 revenue reached $281M versus a $204.31M consensus as clinical therapy selection cases rose 20% to 52,700, and FY25 revenue guidance of $800M tops $723.42M estimates.
1. Baird Initiates Coverage with Outperform Rating
On February 17, Baird initiated coverage of Caris Life Sciences with an Outperform rating and a $26 price target, highlighting the company’s commercial-stage precision oncology platform that leverages comprehensive molecular profiling and machine learning algorithms.
2. Fourth-Quarter Revenue Beat
Caris reported fourth-quarter revenue of $281 million compared to a $204.31 million consensus estimate as clinical therapy selection cases climbed 20% to approximately 52,700, including about 44,150 MI Profile cases and 8,550 Caris Assure cases.
3. FY25 Guidance Exceeds Estimates
For full-year 2025, Caris projects $800 million in revenue versus a $723.42 million consensus, driven by a 22% increase in case volume to roughly 199,300 clinical therapy selection cases.